LONDON, May 26, 2022 /PRNewswire/ — Advent Life Sciences, a leading transatlantic expansion and venture capital investor focused on building cutting-edge life sciences corporations in the UK, Europe and the United States, today announced the appointment of 3 senior members of its team, all industry investment specialists, and to build businesses and help them translate concepts into transformative medicines. Dominic Schmidt, founded in the UK, and Satish Jindal, founded in Boston, USA. Katrine Bosley, founded in Boston, USA, has been named As a General Partner. In the U. S. , it joins as a venture partner. Advent’s investment team now includes 18 professionals with a proven track record of educational marketers and corporations in delivering cutting-edge new medicines.
In the past, Dominic spent 8 years as a spouse on the Syncona investment team, where he helped found, fund and build several life sciences corporations and participated in the forums of Anaveon, Orbit Biomedical, Gyroscope Therapeutics (acquired through Novartis), Purespring Therapeutics and Forcefield. Dominic holds a BA in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics, and a PhD from the Department of Oncology at the University of Cambridge. Dominic was a Cancer Research UK Fellow and his award-winning studies were published in Cell, Nature and Science.
Satish was previously CEO of BioMotiv, a start-up investment fund. Satish was co-founder and CEO of NeoGenesis (acquired through Schering-Plough, now Merck), co-founder and chairman of Verastem (NADAQ: VSTM) and co-founder of Elicio Therapeutics. He also served as vice president and site manager at the Schering-Plough Research Institute in Cambridge, Massachusetts, and vice president at Bristol-Myers Squibb. Satish’s PhD in Biochemistry is from the University of Punjab in India. He completed his postdoctoral studies at MIT’s Whitehead Institute.
Katrine is an entrepreneur with over 30 years of experience in the biotech industry. She is chair of the board of directors of Arrakis Therapeutics, founding CEO of DaCapo Brainscience and a member of the board of directors of Genocea Biosciences. Katrine was CEO of Editas Medicine, the first company created to expand CRISPR-based gene-editing therapies. Prior to that, she was CEO of Avila Therapeutics and held positions at Broad Institute, Adnexus Therapeutics, Biogen, Highland Capital Partners and Alkermes. Katrine has been identified as one of the hundred most creative people in business through Fast Company, as CEO of the year through Xconomy, as one of the 30 Global Game Changers through Forbes, as entrepreneur of the year through the New England Venture Capital Association and as one of the ten most sensible women in biotechnology through Fierce Biotech.
Shahzad Malik, General Partner of Advent Life Sciences, said: “I am very pleased to welcome Dominic, Satish and Katrine. They bring a wealth of experience to our talented team. Since its launch, Advent Life Sciences has invested in drug studies and advertising. progress in the university interface with the identification and support of high-potential inventions that can offer new medicines vital to unmet medical needs. devastating diseases. “
Dominic Schmidt, Managing Partner of Advent Life Sciences, said: “Advent is one of europe’s leading life sciences venture capital firms, with a long and successful track record that has resulted in the impressive approval of 14 medicines and products to gain patient advantages. “I look to the future to work with such a pragmatic and entrepreneurial team that supports Advent’s long-standing successful strategy of supporting high-potential life sciences companies. “
Satish Jindal, General Partner at Advent Life Sciences, said: “It is a great emotion to join the exceptional team at Advent, which has founded more than 35 new biotechnology corporations that are focused on translating educational studies into the next generation of medicines. This level of progression in the life sciences is neglected and we have a keen interest in supporting startups in the critical early years. “
Katrine Bosley, Venture Partner, Advent Life Sciences, said: “I am very pleased to join the Advent team and provide help in the marketplace in Boston, USA. In the U. S. , right at the center of the world’s largest biotech expertise. hub. Venture capital investment is critical to the development of new medicines, more than ever in these turbulent times in public markets, and will continue to have a real impact on patients, as well as strong financial returns. “
About Advent Life Sciences
Advent Life Sciences founds and invests in early- and mid-stage life sciences corporations that have best-in-class technique for addressing unmet medical needs. The investment team is comprised of experienced professionals, each with extensive scientific, medical and operational experience, a long history of business goodwill and investment in the U. S. In the U. S. and Europe, and with a specific focus on supporting marketers and founders to bring out new medical entities at the forefront of the concept. The company invests in a diversity of life sciences sectors, primarily drug discovery, enabling technologies and medical technology, with a focus on cutting-edge techniques that replace paradigms. Advent Life Sciences is offered in the UK, USA, and Canada. For more information, visit www. AdventLS. com